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Abstract
Recent studies have shown increased concentration of fetal hemoglobin (HbF) in pre-
eclamptic women. Plasma hemopexin (Hpx) and alpha-1-microglobulin (A1M) are hemoglo-
bin scavenger proteins that protect against toxic effects of free heme released in the hemo-
globin degradation process. We used an enzyme-linked immunosorbent assay to analyze
maternal plasma Hpx and A1M concentrations at 12–14, 18–20 and 26–28 weeks of gesta-
tion in three groups: 1) 51 women with a low risk for pre-eclampsia (LRW), 2) 49 women with
a high risk for pre-eclampsia (PE) who did not develop PE (HRW) and 3) 42 women with a
high risk for PE who developed PE (HRPE). The study had three aims: 1) to investigate
whether longitudinal differences exist between study groups, 2) to examine if Hpx and A1M
concentrations develop differently in pre-eclamptic women with small for gestational age
(SGA) fetuses vs. pre-eclamptic women with appropriate for gestational age fetuses, and 3)
to examine if longitudinal Hpx and A1M profiles differ by PE subtype (early-onset vs. late-
onset and severe vs. non-severe PE). Repeated measures analysis of variance was used to
analyze differences in Hpx and A1M concentrations between the groups. We found that the
differences in longitudinal plasma Hpx and A1M concentrations in HRW compared to HRPE
and to LRW may be associated with reduced risk of PE regardless of clinical risk factors. In
women who developed PE, a high A1M concentration from midgestation to late second
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trimester was associated with SGA. There were no differences in longitudinal Hpx and A1M
concentrations from first to late second trimester in high-risk women who developed early-
onset or. late-onset PE or in women who developed severe or. non-severe PE.
Introduction
Pre-eclampsia (PE) is a hypertensive disease that occurs in 2–8% of pregnancies. Globally,
PE is a major cause of maternal and fetal morbidity and mortality [1, 2] and it indicates an
elevated risk for subsequent long-term, non-communicable diseases of the mother and the
newborn child [3, 4]. The exact cause of PE is unknown, but the understanding of the patho-
physiological mechanisms of the disease has increased gradually. Currently, most popular the-
ory is that the disease develops in two stages. The first stage occurs during early placental
development, when impaired invasion of extravillous trophoblasts to the maternal spiral
arteries causes defective remodeling of the arteries and incomplete vascular adaptation to
pregnancy [5]. This causes uneven blood flow in the intervillous space of the placenta [6],
intermittent hypoxia and oxidative stress [7]. Damages to the placenta-blood barrier follows
and there is increased leakage of placental and fetal products into the maternal blood circula-
tion [8–10]. It is known that poor placentation is associated with early-onset PE and small for
gestational age (SGA) neonates, which may or may not be associated with PE [11].
The second stage of PE occurs later in pregnancy, after 20 weeks of gestation (GW) and the
typical clinical manifestations are hypertension and proteinuria. This stage is characterized by
endothelial dysfunction [12], maternal hypovolemia, vasoconstriction [13] and inflammation
[14]. Circulating toxic factors derived from the placenta trigger an inflammatory response and
induce general endothelial dysfunction. General organ damage develops, which, in turn, leads
to the typical clinical manifestations of PE. Maternal susceptibility and certain maternal char-
acteristics (e.g., obesity, metabolic syndrome, hypertension) play an important role at this
stage [11, 15].
Earlier studies suggest that the plasma concentrations of free fetal hemoglobin (HbF) are
increased in women who will develop PE and that HbF plays an important role bridging stage
I and II [16–19]. The production of HbF is increased in PE placentas [20]. Extracellular HbF
induces oxidative stress by forming reactive oxygen species (ROS). This, in turn, may result in
damage to the placenta-blood barrier and leakage of extracellular HbF into the maternal circu-
lation. Circulating extracellular hemoglobin (Hb) itself is a potent toxin, and free heme
released during the degradation process of Hb exerts also oxidative and toxic effects on sur-
rounding cells and tissue [21]. In fact, high levels of cell-free HbF in the umbilical cord corre-
late with fetal growth restriction (FGR) [22].
Hemopexin (Hpx) and alpha-1-microglobulin (A1M) are proteins involved in the hemo-
globin scavenger system that protects against the toxic effects of free heme released during Hb
degradation. Haptoglobin binds Hb and is the primary protective scavenger protein. Hemo-
pexin has high affinity to free heme and is regarded as a back-up system when the Hb-binding
capacity of haptoglobin is exceeded [23], although it does function independently of haptoglo-
bin and does not require total haptoglobin depletion [24]. Plasma Hpx directs heme primarily
to the parenchymal cells of the liver for catabolism, iron storage and redistribution; by binding
free heme Hpx protects the endothelium [25]. Hpx has also enzymatic activity which increases
during pregnancy and may be lead to reduced angiotensin II sensitivity during normal preg-
nancy [26]. A1M has heme-binding and heme-degrading [27] as well as enzymatic reductase
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properties which counteract heme-induced and ROS-induced cellular oxidation [28]. Both
Hpx and A1M are potential biomarkers for predicting PE [19, 29] and several reports suggest
that A1M may be a therapeutic target for PE [30–32], the most recent one for the mice PE
model Storkhead box 1 (STOX-1) [33].
There are studies on plasma Hpx and A1M concentrations during the first trimester of
pregnancy [19] and after manifestation of PE in late pregnancy [29]. In a previous study on
maternal plasma Hpx and A1M concentrations in late second trimester we found that, during
26–28 GW, women at high risk for PE who did not develop PE had higher A1M concentrations
than women at high risk who did develop PE [34]. In the present study we followed the plasma
concentrations of these hemoglobin scavenger proteins at three time points during pregnancy
in three different groups: women with a low risk for PE, in women with a high risk for PE who
did not develop PE and in women with a high risk for PE who did develop PE. The focus in this
study is on the longitudinal changes of Hpx and A1M concentrations during pregnancy. The
aim was to clarify whether there are differences in Hpx and A1M concentrations longitudinally
between the study groups and to increase our understanding of the pathophysiology of PE.
A recent study showed that the toxicity of HbF causes pathophysiological processes which
lead to a compromised feto-placental circulation and FGR [22]. Since HbF is toxic to the fetus,
the role of Hpx and A1M was also evaluated in women with PE who experienced FGR compli-
cations and who did not experience FGR complications. For this, we studied pre-eclamptic
women with an SGA fetus (PESGA) and high-risk women who developed PE and who deliv-
ered an appropriate for gestational age (AGA) neonate (PEAGA).
Our third aim was to investigate if there are differences in longitudinal Hpx and A1M con-
centrations depending on the subtype of the PE, i.e., between early-onset PE vs. late-onset PE
and between non-severe vs. severe PE.
Materials and methods
This nested case-control study is a part of the multidisciplinary Prediction and Prevention of
Pre-eclampsia and Intrauterine Growth Restriction (PREDO) project [35]. Women with known
risk factors for PE were prospectively recruited between September 2005 and June 2009 at ten
maternity clinics in Finland. The ethics Committee of the Helsinki and Uusimaa Hospital Dis-
trict approved the study and written informed consent was obtained from all participants.
In total 142 women were included: 42 women with PE (HRPE), 49 randomly selected high-
risk women who did not develop PE (HRW) and 51 low-risk women (LRW). Seven women in
the HRPE participated also in the acetylsalicylic acid (ASA) trial arm of the PREDO project
and were treated with a daily low oral dose of acetylsalicylic acid (LDA 100 mg/d) starting
before 14th GW. The inclusion and exclusion criteria are described in Table 1 and the flow-
chart in Fig 1.
The criteria for PE were systolic blood pressure� 140 mmHg and/or a diastolic blood
pressure� 90 mmHg after 20 GW and a urinary 24-h protein excretion of� 0.3 g or dipstick
equivalent in two consecutive measurements. Pre-eclampsia superimposed on chronic hyper-
tension were included in the primary outcome. Secondary outcomes were PE combined with
SGA infant, early-onset pre-eclampsia (diagnosed before 34+0 weeks of gestation) and severe
pre-eclampsia (systolic blood pressure� 160 mmHg and/or diastolic blood pressure� 110
mmHg and/or proteinuria� 5 g/24 hours). SGA was defined as a birthweight� - 2 SDs [36].
All participants had their first visit at 12–14 GW. Uterine artery blood flow was measured
with Doppler sonography. Gestational age was confirmed by crown-rump length measure-
ment. The first-trimester mean arterial pressure (MAP) was calculated with the equation:
MAP = diastolic blood pressure + (systolic blood pressure–diastolic blood pressure)/3.
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The plasma Hpx concentration was measured using a sandwich ELISA kit (Human Hemo-
pexin, Genway Biotech Inc., San Diego, CA, USA) and a multilabel counter (Wallac 1420, Per-
kin-Elmer, Wallac, Turku, Finland) (absorbance at 450nm).
Table 1. Inclusion and exclusion criteria for high-risk women.
Inclusion criteria
Obesity (body mass index over 30 kg/m2)
Chronic hypertension (�140/90 mmHg or antihypertensive medication before GW 20)
Sjo¨gren’s syndrome
History of gestational diabetes
History of pre-eclampsia (blood pressure�140 mmHg systolic or�90 mmHg diastolic
and proteinuria�0.3 g/day or dipstick equivalent in two consecutive measurements)
History of small for gestational age (birthweight< -2SD)
History of fetus mortus (fetal death after 22 weeks of gestation or >500 g weight in a previous pregnancy)
Systemic lupus erythematosus
Type 1 diabetes mellitus
Exclusion criteria
Tobacco smoking (during this pregnancy)
Multiple pregnancy
History of asthma
History of peptic ulcer
Placental ablation
Inflammatory bowel diseases (Crohn’s disease, ulcerative colitis)
Rheumatoid arthritis
Hemophilia or thrombophilia (previous venous or pulmonary thrombosis or coagulopathy)
https://doi.org/10.1371/journal.pone.0226520.t001
Fig 1. Flowchart of study cohort. PE = pre-eclampsia, SGA = small for gestational age, AGA = appropriate for
gestational age.
https://doi.org/10.1371/journal.pone.0226520.g001
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Plasma A1M concentration was measured using an in-house ELISA and microtiter plates,
which were coated with mouse monoclonal anti-A1M antibodies (clone 35.14). The monoclo-
nal anti-A1M antibodies were produced against human urinary A1M by Agrisera AB (Va¨nna¨s,
Sweden). Human urinary A1M was prepared in the laboratory of the Section for Infection
Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, as described ear-
lier [37].
Briefly, the plasma samples were incubated overnight at +4˚C under sealing film in 5 μg/ml
solution of phosphate buffered saline (PBS) buffer (+ 0.05% tween-20, 100 μl/well). After wash-
ing three times with PBS buffer, 100 μl of human urinary A1M reference standard (1.56–100
ng/ml in PBS buffer) or unknown diluted plasma samples (1:1000 with PBS buffer) were
added to the wells and incubated for 1 h at room temperature, in darkness and on a rotational
shaker (250–500 rpm). After washing three times with PBS buffer, 100 μl of the detection anti-
body solution was added (horseradish peroxidase-coupled mouse monoclonal anti-A1M anti-
body clone 57.10; in PBS) and incubated for 1 h at room temperature, in darkness and on a
rotational shaker (250–300 rpm). After washing three times with PBS, 100 μl of 3,3’,5,5’-tetra-
methylbenzidine (TMB substrate, SureBlueTM TMB Microwell Peroxidase Substrate, KPL cat.
no. 50-00-04) was added, sealed and again incubated for 20 min without shaking, and the reac-
tion was stopped by adding 100 μl of 1 M sulfuric acid. Absorbance at 450 nm was read using
the same Wallac 1420 Multilabel Counter.
Statistical analyses
Data was analyzed for normality. The differences of means of normally distributed baseline
variables between the groups were analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s post-hoc tests. The Kruskal-Wallis test was used if the data was not normally
distributed. Comparisons of medians of non-normally distributed variables were made with
Mann-Whitney’s U test. Bonferroni corrections were used in post-hoc comparisons. Categori-
cal variables were compared with Fisher’s exact test and in pairwise comparisons Bonferroni
correction was used.
Repeated measures analysis of variance (RMANOVA) was used to analyze differences in
plasma Hpx and A1M concentrations between the groups. The model included the main
effects of time, group and the interaction effect time x group. Log-transformed Hpx and A1M
values were used in these analyses due to positively skewed distributions. The best covariance
structure was selected by using AICC (Akaike information criterion with a correction for
small sample sizes) and compound symmetry covariance structure was chosen. The results of
the values for Hpx and A1M are expressed as geometric means with 95% confidence intervals.
One-way ANOVA followed by Tukey’s post-hoc tests was used for multiple comparisons of
biomarker concentrations at each sampling point, if further analyses were indicated after
RMANOVA. In all analyses a p-value < 0.05 was considered statistically significant. Statistical
analyses were performed using version 25.0 of the SPSS statistic software package.
Results
Baseline characteristics
The baseline characteristics of LRW, HRW and HRPE are shown in Table 2 including the divi-
sion of HRPE into two groups: 1. PESGA and 2. PEAGA. One woman in the HRW group had
type 1 diabetes mellitus and one had Sjo¨gren´s syndrome (Table 2). HRW and HRPE were
older (p = 0.007) and had a higher body mass index (BMI) (p<0.001) than LRW. There were
more women with chronic disease in the HRW and HRPE groups than in in the LRW group
(p<0.001). Due to the inclusion criteria of the study there were, in the HRW and HRPE groups
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compared to the LRW group, less primiparous women (p<0.001) and more women with prior
SGA (p = 0.002), BMI� 30 kg/m2 (p<0.001), chronic hypertension (p<0.001), prior PE
(p<0.001) and prior gestational diabetes (p = 0.041).
Pregnancy characteristics
The pregnancy characteristics of LRW, HRW and HRPE and the subgroups of SGAPE and
AGAPE are shown in Table 3. LRW gained more weight during pregnancy compared to HRW
and HRPE (p = 0.009 and p = 0.028, respectively) and the mean uterine artery pulsatility index
in the first trimester was lower (p<0.001 for both comparisons). There was more gestational
diabetes in HRW and HRPE compared to LRW (p = 0.014). Women in the HRPE group deliv-
ered earlier than in the HRW or LRW groups (p<0.001) and in the HRW group earlier than in
the LRW group (p<0.001). There were more deliveries with vacuum extraction among HRW
than HRPE and LRW (p = 0.006). Women in the HRPE group delivered smaller infants than
in the HRW (p<0.001) or LRW (p = 0.015) groups. There was no difference in birth weight
SD score between HRW and LRW (p = 0.146). Women in the PESGA group delivered earlier
(median 31.9 GW) than in the other groups (p<0.001 in all pairwise comparisons).
Outcomes
PE phenotypes are shown in Table 4. Of 42 women who developed PE, 33 (79%) gave birth to
an AGA infant and 9 (21%) to an SGA infant. There were 21 women with severe and non-
severe PE, respectively. Eleven women (26%) had early-onset PE and 32 (78%) late-onset PE.
Table 2. Baseline characteristics of study groups.
Characteristics LRW N = 51 HRW N = 49 HRPE N = 42 PEAGA n = 33 PESGA n = 9
Age, yearsa 29 (5) 33 (6) 31(6) 31.0(6.5) 31.0(8.0)
BMI, pre-pregnancy, kg/m2 b 22.6 (2.4) 28.5 (9.7) 29.3(10.6) 29.6(11.0) 29.0(14.8)
Primiparous, n (%)c 30 (59) 12 (25) 10(24) 6(18.20) 4(44.4)
Infertility treatment, n (%) 4 (9) 7 (15) 5(14) 4(14.8) 1(11.1)
Chronic disease, n (%)c 10 (17) 27 (46) 22(37) 17(51.5) 5(55.6)
BMI� 30 kg/m2 c 1 (3) 21(43) 16(38) 13(38.2) 3(37.5)
Prior pre-eclampsia, n (%)c 0 14(29) 21(50) 19(57.6) 2(22.2)
SGA in previous pregnancy, n (%)d 0 9(18) 4(10) 2(6.1) 2(22.2)
Chronic hypertensionc 0 14 (29) 10(24) 8(24.2) 2(22.2)
Prior GDM, n (%)e 0 5 (10) 4(10) 4(11.8) 0(0.0)
Type 1 DM, n (%)f 0(0.0) 1(2.0) 0(0.0) 0(0.0) 0(0.0)
Prior fetus mortus, n (%) 0 2(4) 1(2) 1(2.9) 0(0.0)
SLE, n (%) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0)
Sjo¨gren´s syndrome, n (%) 0(0.0) 1(2.0) 0(0.0) 0(0.0) 0(0.0)
a Difference across the groups p < 0.001, no difference across the high-risk groups, median and IQR presented
b Difference between LRW vs. HRW or HRPE, p<0.001 for both comparisons, median and IQR presented
c Difference across the groups (p<0.001), no difference across the high-risk groups
d Difference across the groups (p = 0.002), no difference across the high-risk groups
e Difference across the groups (p = 0.041), no difference across the high-risk groups
LRW = low-risk women, HRW = high-risk women, HRPE = high-risk women who developed pre-eclampsia, PEAGA = pre-eclamptic women with appropriate for
gestational age fetuses, PESGA = pre-eclamptic women with small for gestational age fetuses, IQR = interquartile range, BMI = body mass index, SGA = small for
gestational age, GDM = gestational diabetes, DM = diabetes mellitus, SLE = systemic lupus erythematosus
https://doi.org/10.1371/journal.pone.0226520.t002
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Table 3. Pregnancy characteristics of study groups.
Pregnancy characteristics LRW
N = 51
HRW N = 49 HRPE
N = 42
PEAGA n = 33 PESGA n = 9
Weight gain during pregnancy, kg(%)a 14.8(5.5) 11.7(9.0) 12.0(6.6) 12.3 (5.4) 11.1(10.4)
Gestational diabetes, n(%)b 4 (7.8) 13(26.5) 12(28.6) 10 (30.3) 2(22.2)
I trimester mean UTA PI 0.93(0.26)c 1.07(0.40)d 1.25(0.47)e 1.19(0.48)f 1.41(0.42)g
I trimester MAP, mmHgh 86.3(7.7) 97.0 (11.4) 101.6(13.3) 100.6 (13.0) 105.2(14.5)
Highest MAP, mmHgi 94.0(9.7) 105.0(12.7) 127.8(10.8) 128.3(16.7) 128.7(14.5)
Highest proteinuria, g/dayj 0 0 1.5(2.3) 1.06(2.18) 2.30(5.20)
Gestational weeks at birthk 40.6(1.3) 39.9 (2.1) 38.4(3.2) 38.7(2.4) 31.9(5.6)
Mode of delivery, n (%)
Vaginal 33 (65.0) 34 (69.4) 26 (61.9) 20 (61.0) 6 (66.7)
Vacuum extractionk 8 (16.0) 0 (0.0) 6 (14.3) 5 (15.2) 1 (11.1)
Elective cesarean section 1 (2.0) 3 (6.1) 1 (2.4) 0 (0.0) 1 (11.1)
Cesarean section during labor 8 (16.0) 12 (24.5) 8 (19.0) 7 (21.2) 1 (11.1)
Umbilical artery pHl 7.24 (0.09) 7.27(0.08) 7.27(0.08) 7.24(0.09) 7.22(0.11)
Newborn birthweight, gm 3524 (582) 3690(712) 3109(1259) 3370(687) 1358(1125)
Newborn birthweight, SD scoren -0.11 0.38 -0.78 -0.30 -2.51
Placental weight, go 594(111) 641(128) 537(158) 582(143) 367(71)
LRW = low-risk women, HRW = high-risk women, HRPE = high-risk women who developed pre-eclampsia, PEAGA = women, who developed pre-eclampsia and had
appropriate for gestational age fetuses, PESGA = women, who developed pre-eclampsia and had small for gestational age fetuses, UTA PI = uterine artery pulsatility
index, MAP = mean arterial pressure, IQR = interquartile range, SD = standard deviation
a Difference across the groups (p = 0.015), no difference across the high-risk groups, median and IQR presented
b Difference across the groups (p = 0.025), no difference across the high-risk groups
c Differed from d and e, p<0.001 and from f (p = 0.006) and g (p = <0.001), f differed from g (p = 0.018), median and IQR presented
h Difference across the groups (p<0.001), no difference across the high-risk groups, mean and SD presented
i Difference between the groups (p<0.001) except between AGAPE vs. SGAPE, median and IQR presented
j No difference between AGAPE with SGAPE, median and IQR presented
k high-risk controls differed from low-risk women and high-risk women with subsequent PE, p = 0.006
l Difference between the groups (the highest p = 0.018) except between LRW vs. HRW, median and IQR presented
m No difference between the groups, mean and SD presented
n HRPE differed from HRW and LRW, p<0.001 and p = 0.003, respectively. SGAPE differed from LRW, HRW and AGASGA (all p-values <0.001) and AGAPE
differed from HRW (p = 0.018), median and IQR presented
o HRPE differed from LRW and HRW (p = 0.015 and p<0.001, respectively), SGAPE differed from other groups (p<0.001), mean presented
p Difference between HRW and HRPE ((p = 0.001), SGAPE differed from other groups (p<0.001), mean and SD presented
https://doi.org/10.1371/journal.pone.0226520.t003
Table 4. Distribution of pre-eclampsia phenotypes.
Women with SGA fetus n Women with AGA fetus n
Severe EOPE 7 Severe EOPE 3
Non-severe EOPE 0 Non-severe EOPE 1
Severe LOPE 1 Severe LOPE 10
Non-severe LOPE 1 Non-severe LOPE 19
Total 9 33
SGA = small for gestational age, AGA = appropriate for gestational age, n = number of women, EOPE = early-onset
pre-eclampsia, LOPE = late-onset pre-eclampsia
https://doi.org/10.1371/journal.pone.0226520.t004
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Correlation and covariates
The Hpx and A1M concentrations of LRW at 12–14 GW correlated positively, after logarith-
mic normalization of the data, (Pearson r = 0.33, p = 0.022), as did they in the HRW group at
18–20 GW (Pearson r = 0.30, p = 0.039). Hpx and A1M concentrations did not correlate in
other respects. The BMI was a significant covariate for the Hpx (main effect BMI, p = 0.001 in
the RMANOVA model, Pearson r = 0.20, p<0.001), but not for the A1M concentration.
Therefore, the Hpx concentration was adjusted for BMI. Also other covariates were tested:
Hpx and A1M concentrations were adjusted for maternal age, ASA usage, gestational diabetes,
MAP in the first trimester and mean uterine artery pulsatility index. None of the tested vari-
ables turned out to be a significant covariate for Hpx or for A1M.
Hemopexin and alpha-1-microglobulin concentrations
At first trimester sampling the mean GW was 13.0 (11.9–15.9), at second sampling 19.4 GW
(18.0–21.3) and at third sampling 27.1 GW (25.0–28.7). The geometric mean plasma concen-
trations of Hpx, Hpx adjusted for BMI and A1M are shown in Tables 5A, 5B and 6,
respectively.
Hemopexin
All pre-eclampsia vs. controls. There was a difference in the plasma Hpx concentration
and the change of the Hpx concentration between the three study groups, main effect Group,
p = 0.002 and interaction effect Time x group, p = 0.021 (Table 5A, Fig 2A), and the result
remained significant after adjustment for BMI, main effect Group, p = 0.004 and interaction
effect Time x group, p = 0.010 (Table 5B and Fig 2B). When adjusted for BMI, the plasma con-
centration of hemopexin in the LRW and HRPE groups changed similarly from 12–14 to 26–
28 weeks of gestation (main effect Group, p = 0.374, interaction effect Time x group,
p = 0.063) while the Hpx concentration of HRW was at the same level throughout the study
period and therefore differed from the Hpx concentration of LRW and HRPE (interaction
effect Time x group, p = 0.006, Fig 2B).
The level of plasma Hpx in the HRW group during the first half of the pregnancy (from 12–
14 to 18–20 GW) was lower than in the LRW and HRPE groups (main effect Group, p = 0.001,
Table 5A, Fig 2A). This difference persisted after adjustment for BMI (main effect Group,
p<0.001, Table 5B, Fig 2B).
After midgestation, the mean Hpx concentration decreased in the LRW group (-0.16 mg/
ml) and increased slightly in the HRW group (0.01 mg/ml). These changes differed signifi-
cantly from each other (p = 0.012) over time (between 18–20 and 26–28 GW). During the
same period, the mean Hpx concentrations were higher in the HRPE than the LRW group
(main effect Group, p = 0.015, changes in Hpx concentration -0.05 vs. -0.16, respectively,
p = 0.056) and the HRW group (main effect Group, p = 0.039). The changes in Hpx concentra-
tions did not differ between HRPE and HRW after midgestation (-0.05 vs. 0.01, respectively,
p = 1.000, Table 5A, Fig 2A). After adjustment for BMI there was no difference in the Hpx con-
centration between LRC and HRPE.
Small for gestational age and appropriate for gestational age (Table 5). The mean
plasma Hpx concentration in the PESGA group decreased over time from 12–14 to 26–28
GW, but in the PEAGA group it remained at the same level from 12–14 to 18–20 GW and
then decreased from 18–20 to 26–28 GW. These differences between PESGA and PEAGA
were not statistically significant (main effect Group, p = 0.449, interaction effect Time x group,
p = 0.449).
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When analyzed separately at each sampling point, the Hpx concentration in the PEAGA
group was higher than in the HRW group (1.27 vs. 1.11 mg/ml, respectively, p = 0.020) at 18–
20 GW. At 26–28 GW PEAGA had a higher Hpx concentration than LRW (1.22 vs. 1.03 mg/
ml, respectively, p = 0.004).
Early-onset and late-onset pre-eclampsia (Table 5). Although the Hpx concentrations of
high-risk women who developed late-onset PE compared to high-risk women who developed
early-onset PE were constantly higher at each sampling point, the difference was significant
neither before (main effect Group p = 0.575 and interaction effect Time x group p = 0.998) nor
after adjustment for BMI (p = 0.574 and p = 0.996, respectively).
When analyzed separately at each sampling point, the Hpx concentrations of women who
developed late-onset PE was higher than in HRW at 12–14 GW (1.28 vs. 1.12 mg/ml, respec-
tively, p = 0.034) and at 18–20 GW (1.26 vs. 1.11 mg/ml, respectively, p = 0.041). The Hpx con-
centrations of women who developed late-onset PE was higher than in the LRW group at 26–
28 GW (1.21 vs. 1.03, respectively, p = 0.011).
Table 5. Geometric mean plasma hemopexin concentrations (mg/ml) by subgroups at three different sampling points during pregnancy. A before adjustment for
body mass index, B after adjustment for body mass index.
Table 5. A
Group 12–14 GW 95% CI 18–20 GW 95% CI 26–28� GW 95% CI
Hpx mg/ml Lower Bound Upper Bound Hpx mg/ml Lower Bound Upper Bound Hpx mg/ml Lower Bound Upper Bound
LRW N = 51 1.20 1.13 1.28 1.19 1.12 1.26 1.03e 0.97 1.09
HRW N = 49 1.12a 1.06 1.19 1.11b 1.05 1.18 1.13 1.06 1.20
HRPE N = 42 1.27 1.19 1.36 1.25 1.17 1.33 1.20f 1.12 1.29
PESGA n = 9 1.29 1.11 1.49 1.17 1.02 1.34 1.12 0.97 1.31
PEAGA n = 33 1.27 1.18 1.36 1.27c 1.19 1.36 1.22g 1.13 1.32
EOPE n = 11 1.23 1.08 1.40 1.22 1.08 1.38 1.17 1.02 1.35
LOPE n = 31 1.28a 1.19 1.39 1.26d 1.18 1.36 1.21h 1.12 1.31
SEV n = 21 1.28 1.17 1.41 1.26 1.16 1.38 1.18 1.07 1.31
MILD n = 21 1.26 1.15 1.38 1.24 1.13 1.35 1.22i 1.11 1.35
Table 5. B
Group 12–14 GW 95% CI 18–20 GW 95% CI 26–28� GW 95% CI
Hpx_A mg/ml Lower Bound Upper Bound Hpx_A mg/ml Lower Bound Upper Bound Hpx_A mg/ml Lower Bound Upper Bound
LRW N = 51 1.24 1.17 1.32 1.23 1.17 1.31 1.05 0.99 1.12
HRW N = 49 1.11 1.04 1.17 1.10 1.03 1.16 1.11 1.05 1.18
HRPE N = 42 1.24 1.13 1.31 1.23 1.15 1.31 1.18 1.10 1.26
PESGA n = 9 1.26 1.09 1.47 1.15 1.00 1.31 1.10 0.95 1.28
PEAGA n = 33 1.24 1.14 1.33 1.26 1.17 1.34 1.20 1.11 1.30
EOPE n = 11 1.21 1.06 1.38 1.19 1.06 1.35 1.15 1.00 1.33
LOPE n = 31 1.25 1.16 1.36 1.24 1.16 1.34 1.19 1.09 1.29
SEV n = 21 1.28 1.16 1.40 1.26 1.15 1.37 1.17 1.07 1.30
MILD n = 21 1.20 1.09 1.33 1.21 1.10 1.32 1.17 1.06 1.30
� Published earlier as medians [34].
GW = week of gestation, CI = confidence interval, Hpx = mean hemopexin concentration, A_Hpx = mean hemopexin concentration after adjustment for BMI, LRW =
low-risk women, controls HRW = high-risk women, controls, HRPE = high-risk women who developed pre-eclampsia, EOPE = women who developed early-onset
pre-eclampsia, LOPE = women, who developed late-onset pre-eclampsia, SEV = women, who had severe pre-eclampsia, MILD = women, who had non-severe (mild)
pre-eclampsia, PESGA = women who developed pre-eclampsia and gave birth to an small for gestational age infant, PEAGA = women who developed pre-eclampsia
and gave birth to an appropriate for gestational age infant
a p = 0.034 b lower than c p = 0.020 and d p = 0.041, e lower than f = 0.003, g p = 0.004, h p = 0.011 and i p = 0.029
https://doi.org/10.1371/journal.pone.0226520.t005
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Severe and non-severe pre-eclampsia (Table 5). There was no difference in plasma Hpx
concentrations between high-risk women with severe PE and high-risk women with non-
severe PE neither before (main effect Group p = 0.933, interaction effect Time x group
p = 0.726) nor after adjustment for BMI (main effect Group p = 0.378 and interaction effect
Time x group p = 0.759). When analyzed separately at each sampling point, the Hpx concen-
trations of women who developed non-severe PE were higher than in LRW at 26–28 GW (1.22
vs. 1.03 mg/ml, respectively, p = 0.029).
Alpha-1-microglobulin
All pre-eclampsia vs. controls. There was a difference in A1M concentrations and in the
changes of the concentrations longitudinally between HRPE, HRW and LRW (main effect
Group, p = 0.009 and interaction effect Time x group, p<0.001) (Fig 3A and Table 6). In fur-
ther analyses of A1M, the concentrations of A1M in the HRPE and HRW was higher than in
the LRW group from 12–14 to 18–20 GW (Fig 3A, Table 6, main effect Group, p = 0.021). The
Table 6. Geometric mean plasma alpha-1-microglobulin concentration (μg/ml) by subgroups at three different sampling points during pregnancy.
Group 12–14 GW 95% CI 18–20 GW 95% CI 26–28� GW 95% CI
A1M μg/ml Lower Bound Upper Bound A1M μg/ml Lower Bound Upper Bound A1M μg/ml Lower Bound Upper Bound
LRW N = 51 12.0a 11.0 13.0 11.9g 11.0 12.9 12.7m 11.6 13.7
HRW N = 49 12.9b 11.8 14.0 14.6h 13.5 15.9 15.2n 14.0 16.5
HRPE N = 42 15.6c 14.2 17.0 12.7i 11.7 13.9 13.7 12.5 15.0
PESGA n = 9 15.5 12.7 19.0 15.4 12.8 18.6 17.6o 14.5 21.3
PEAGA n = 33 15.5d 14.0 17.1 12.1j 11.0 13.3 12.8 11.6 14.1
EOPE n = 11 15.9 13.3 19.0 14.6 12.3 17.4 16.1 13.5 19.2
LOPE n = 31 15.4e 13.9 17.1 12.1k 11.0 13.4 13.0 11.7 14.4
SEV n = 21 16.6f 14.6 18.9 13.7 12.1 15.5 15.1 13.3 17.2
MILD n = 21 14.6 12.8 16.5 11.8l 10.5 13.4 12.4p 10.9 14.1
� Published earlier as medians [34].
GW = weeks of gestation, CI = confidence interval, A1M = mean alpha-1-microglobulin concentration, LRW = low-risk women, HRW = high-risk women, HRPE =
high-risk women who developed pre-eclampsia, PESGA = women who developed pre-eclampsia and gave birth to an small for gestational age infant, PEAGA = women
who developed pre-eclampsia and gave birth to an appropriate for gestational age infant, EOPE = women who developed early-onset pre-eclampsia, LOPE = women,
who developed late-onset pre-eclampsia, SEV = women, who had severe pre-eclampsia, MILD = women, who had non-severe (mild) pre-eclampsia
a vs. b p = 0.017, a vs. c p<0.001, a vs. d p = 0.017, a vs. e p = 0.002, a vs. f p = 0.001, b vs. d p = 0.036, b vs. f p = 0.017, g vs. h p = 0.001, h vs. i p = 0.038, h vs. j
p = 0.020, h vs. k p = 0.028, h vs. l p = 0.026, m vs. n p = 0.005, m vs. o p = 0.032, n vs. p p = 0.048
https://doi.org/10.1371/journal.pone.0226520.t006
Fig 2. Geometric mean of plasma hemopexin concentration in three study groups by duration of gestation. The
geometric means and the 95% confidence intervals (red bars) of the plasma hemopexin (Hpx) concentration among
low-risk women (LRW) and high-risk women who did (HRPE) and did not (HRW) develop pre-eclampsia. Data
shown by weeks of gestation (A) before and (B) after adjustment for body mass index.
https://doi.org/10.1371/journal.pone.0226520.g002
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mean concentration of A1M in the HRPE decreased more than in the LRW (-2.8 vs. -0.1 μg/
ml, interaction effect Time x group, p<0.001) from 12–14 to 18–20 GW. While the A1M con-
centration in the HRPE decreased, the A1M concentration in HRW increased (-2.8 vs. 1.8 μg/
ml, respectively, interaction effect Time x group, p<0.001) between the first sampling at 12–14
GW and the second sampling at 18–20 GW. The change in A1M in the HRW and LRW groups
between 12–14 and 18–20 GW differed also (1.8 vs. -0.1μg/ml, interaction effect Time x group,
p<0.001). The A1M concentration in the HRW group was higher compared to the LRW and
HRPE groups between the second sampling point at 18–20 GW and the third sampling point
at 26–28 GW (main effect Group, p = 0.002).
Small for gestational age and appropriate for gestational age (Table 6). The mean
plasma A1M concentration in the PEAGA group decreased from 12–14 to 18–20 GW com-
pared to PESGA, but the change was not statistically significant (-3.4 μg/ml vs. -0.1 μg/ml
interaction effect Time x group, p = 0.011, after Bonferroni correction p = 0.066). From mid-
gestation onwards (from 18–20 to 26–28 GW) the A1M concentration was higher in the
PESGA group compared to the PEAGA group (main effect Group, p = 0.008, after Bonferroni
correction p = 0.048) (Fig 3B).
Early-onset and late-onset pre-eclampsia (Table 6). The mean plasma A1M concentra-
tion among high-risk women who developed early-onset PE was constantly higher at each sam-
pling point than among high-risk women who developed late-onset PE. The difference was not
significant (main effect Group p = 0.134 and interaction effect Time x group p = 0.082).
Severe and non-severe pre-eclampsia (Table 6). The mean plasma A1M concentration
was higher at each of the three sampling points among high-risk women who developed severe
PE compared to high-risk women who developed non-severe PE. However, the difference was
not significant (main effect Group p = 0.055, interaction effect Time x group p = 0.668).
Effects of LDA treatment on biomarker concentrations
Ten women had LDA treatment from the first trimester until 35 GW. Three of these women
were in the HRW, seven in the HRPE group. Although women with LDA treatment were
unevenly distributed between the study groups (p = 0.022), the mean Hpx and A1M concen-
trations did not differ between women who did and did not have LDA treatment (S1 Table).
LDA usage was not a significant covariate in RMANOVA for Hpx (p = 0.196) or for A1M
(p = 0.312).
Fig 3. Geometric mean of alpha-1-microglobulin concentration in three study groups and in pre-eclamptic
women with small for gestational age and appropriate for gestational age fetus by weeks of gestation. The
geometric means of the plasma alpha-1-microglobulin (A1M) concentration by weeks of gestation (A) among low-risk
women (LRW) and high-risk women, who developed pre-eclampsia (HRPE) and among high-risk women who did
not develop pre-eclampsia (HRW) and (B) among women who developed pre-eclampsia and gave birth to a small for
gestational age infant (PESGA) and to an appropriate for gestational age infant (PEAGA). Red bars indicate 95%
confidence intervals.
https://doi.org/10.1371/journal.pone.0226520.g003
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Discussion
To our knowledge, this is the first study to investigate plasma Hpx and A1M concentrations
over the duration of pregnancy among women at high risk for PE (some of whom ultimately
developed PE) and among women at low risk for PE.
Since there are no studies on longitudinal plasma Hpx values during pregnancy, the natural
variations of plasma Hpx concentration over the duration of normal pregnancy are not
known. We hypothesized that the longitudinal Hpx concentration would be lower in HRPE
compared to the other groups due to a PE-induced increase in HbF levels in the maternal cir-
culation and by subsequent activation of the Hb scavenger system, which in turn would cause
Hpx depletion. However, the plasma Hpx concentration among the HRPE did not differ from
the plasma Hpx concentration among the LRW and it was significantly higher compared to
the HRW during the first half of pregnancy, suggesting a protective role for low Hpx concen-
tration in HRW. There is some contradiction between our study results and those of Anderson
et al. who found that plasma collected in the first trimester had lower Hpx concentrations
among women who subsequently developed early-onset PE compared to women who did not
develop PE [19]. The discrepancy is due to the multifactorial mechanisms affecting the con-
centration and activity of Hpx. Changes in the plasma hemopexin concentration reflect the
balance between, on the one hand, hepatic synthesis of Hpx and, on the other, depletion of
Hpx due to heme scavenging.
It is also of note that Hpx is an acute-phase plasma protein and its expression and activity
may be modulated by conditions associated with systemic inflammations and oxidative stress
mediated by ROS. The expression of Hpx can be induced through a ROS-dependent mecha-
nism in type 1 diabetes mellitus [38]. In the same way, the expression of Hpx might be induced
in PE during pregnancy due to ROS-mediated oxidative stress, which would explain the
increased level of hemopexin in PE as shown in the present study, where the obesity, diabetes
mellitus and chronic hypertension were among the inclusion criteria of women with high-risk
pregnancies. These conditions are known to induce oxidative stress mediated by ROS and
might predispose to increased plasma Hpx concentrations [39–41].
Some of the differences in mean Hpx concentration between the study groups could be
explained by the effect of BMI, although most of the differences remained significant after
adjustment of the data for BMI. Our hypothesis was that the BMI-adjusted Hpx concentrations
might reflect the role of the placenta in the pathophysiology of PE more reliably. It is, however,
also known that obesity itself is an independent risk factor for PE [42] and therefore it is rele-
vant to present both unadjusted and adjusted results when longitudinal changes in plasma
Hpx concentrations are presented.
In the present study, the plasma Hpx concentration started to decrease from the first tri-
mester in PESGA, as we had hypothesized (Table 5A and 5B). The concentration of cell-free
HbF is higher in the feto-placental circulation in FGR than in normal pregnancies [22]. This
being the case cell-free HbF could very well leak into the maternal circulation, injuring the pla-
cental barrier and leading to Hpx depletion. However, the number of women in this group
was rather small and the difference in Hpx and in the changes in the Hpx concentration were
not statistically significant (Table 5A and 5B). The risk of type II error in this situation is possi-
ble, since the Hpx concentration clearly developed as hypothesized, but the sample size was
small.
The mean plasma A1M concentration was higher in the HRPE than the HRW and LRW in
the first trimester. The present study confirms previous findings [17, 19] (Table 6, Fig 3A) and
contributes additional evidence that suggests differences in A1M changes among pre-eclamp-
tic women, depending on fetal growth (Table 6, Fig 3B). We found that PE women with SGA
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fetuses had consistently higher plasma level of A1M than women in the HRW and LRW, pre-
sumably as a response to increased fetal and maternal cell-free HbF concentrations throughout
the duration of pregnancy. It is tempting to hypothesize that, in cases of PE complicated by
SGA, cell-free HbF, originally present in the feto-placental circulation, leaks into the maternal
circulation, leading to activation of endogenous Hb- and heme-scavenging systems, of which
A1M is an important component. However, cell-free HbF may not be the sole factor affecting
the plasma level of A1M since its synthesis is induced by both cell-free HbF and by ROS [43].
The increased plasma A1M level in the HRW group compared to the LRW group might be
explained as the result of activation of A1M following systemic inflammation and oxidative
stress not related to cell-free HbF. This is speculative since the present study did not study the
plasma cell-free HbF level.
One unexpected finding was that the average plasma level of A1M was lower in the PEAGA
group at midgestation than in the PESGA group. This may be explained by the fact that the
timing of placental dysfunction differs between PESGA and PEAGA. In the latter case, PE
develops later during gestation. According to the revised two-stage model of PE, late-onset PE
develops when the maturing placenta outgrows the capacity of the uterus in late pregnancy,
resulting in restricted intervillous perfusion, syncytiotrophoblast stress and release of several
inflammatory factors into the maternal circulation, including cell-free HbF [44]. It can thus be
anticipated that an increase in the plasma A1M level occurs at later stages of gestation in
PEAGA than in PESGA. In the present study, the plasma A1M level was not evaluated after 28
weeks of gestation, and this leaves this hypothesis unanswered at present. However, the differ-
ent plasma Hpx and A1M profiles in PESGA compared to PEAGA (Table 5 and Table 6) may
reflect earlier and more profound damage of the placenta-blood barrier in PESGA. Hpx is con-
sumed to a higher degree in FGR due to its scavenging property and not as much induced by
ROS as A1M is. While A1M also has scavenging properties, it is induced to a higher degree by
ROS and is more active against ROS than Hpx.
Strength, limitations and recommendations
The strength of the study is a carefully described study cohort, where both women with prede-
termined risk factors for PE and a low-risk reference group were prospectively recruited and
studied.
A limitation of our study is that ten high-risk women had LDA treatment from the first tri-
mester onward until 35+0 GW. These women were unevenly distributed throughout the study
groups. However, LDA use was not a significant covariate for Hpx or A1M concentrations in
RMANOVA.
Due to the case-control set-up, this is a preliminary study and results should be validated in
another cohort.
Conclusions
The present study confirms the results of recent studies that the plasma concentration of A1M
is higher in HRPE compared to HRW and to LRW in the first trimester. We also found that
the concentration of A1M in PESGA remains high during the first half of pregnancy com-
pared, but in PEAGA it decreases. In women who develop PE, high A1M concentration at and
after midgestation is associated with SGA.
HRW have different plasma Hpx and A1M concentrations over time during pregnancy
compared to HRPE and LRW. This phenomenon may be associated with a reduced risk of PE
despite clinical risk factors. Risk factors related to induction of oxidative stress, such as diabe-
tes mellitus, obesity and chronic hypertension, and fetal growth restriction, appeared to be
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significant in this respect. Future risk evaluation should measure the balance between oxidative
stress markers in relation to scavenger proteins such as Hpx and A1M.
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S1 Table. Effects of low-dose acetylsalicylic acid (100mg/d) treatment on biomarker con-
centrations. � ANOVA adjusted for group (HRW or HRPE). Hpx = geometric mean of plasma
hemopexin concentration, A1M = geometric mean of plasma alpha-1-microglobulin concen-
tration, LDA = low-dose acetylsalicylic acid (100mg/d).
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